'The editorial did not beat around the bush. After decades of "expanding opioid use by minimizing the dangers of addiction," Pharma will now receive the reward of taxpayer money to undo what it did andreverse the opioid epidemic, writes the New York Times. Imagine the government giving Big Tobacco our tax dollars to reverse the damage it did pushing cigarettes and you see how obscene this is.
The new public-private partnership between Pharma and the NIH (and supported by both the FDA and DEA) will explore ways to address the opioid crisis such as "nonaddictive painkillers and new treatments for addiction and overdoses."
Not surprisingly, Pharma likes its reward. J. David Haddox, vice president for policy at Purdue Pharma (who makes OxyContin) appreciates the idea of “converting” the opioid market to abuse-deterrent drugs.
But the CEOs of Pharma's lobby group, Pharmaceutical Research and Manufacturers of America or PhRMA, and Purdue Pharma do not appreciate the Times' charges.
There is no reason Pharma shouldn't be involved in "the long-term solutions" for the opioid crisis writes PhRMA CEO Stephen Ubl, calling Pharma operatives "the best minds in science," in a letter to the Times. Craig Landau, CEO of Purdue, appreciates the "regulatory framework to incentivize" Pharma to develop post opioid crisis drugs and writes that Pharma cannot "abandon... pain patients," in a letter to the Times.'
Read more: Funding Big Pharma to Help with Millions of Addicts They Created
Did you like this article?
Thank you for your vote!
15 December 2017
Mainstream Media Now Urging Parents To Give Three-Year-Old Kids Dangerous Drugs For Depression
14 December 2017
A nation of pill poppers: HALF of all adults in England are on prescription drugs for depression and heart disease, damning report reveals
13 December 2017
Chemotherapy found to increase the number of tumor cells circulating in the blood, spreading it to previously unaffected areas
From our advertisers
David Icke - Keith Chegwin, Gary Lineker, Infowars, US underground bases and mainstream media bias
From our advertisers